DGAP-News

Eckert & Ziegler Granted Exclusive Distribution Rights by Telix Pharmaceuticals for Prostate Cancer Diagnostic

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract/Agreement Eckert & Ziegler Granted Exclusive Distribution Rights by Telix Pharmaceuticals for Prostate Cancer Diagnostic 18.05.2021 / 09:14 The issuer is solely responsible for the content of this announcement.

---

Berlin, 18.05.2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed an agreement with Telix Pharmaceuticals (Telix), an Australian-headquartered company, for the exclusive distribution of Illuccix^(R) (Kit for the preparation of Ga-68 PSMA-11 injection) in Germany. Illuccix^(R) is a preparation for imaging prostate cancer with positron emission tomography (PET), currently under review for regulatory approval in multiple markets worldwide, including Germany.

"Illuccix^(R) is anticipated to be one of the most important imaging products for prostate cancer. Widespread approval of a preparation for the diagnosis of prostate cancer is urgently needed and we are pleased to have Telix, a pioneer in bringing this drug to market, as a partner," explained Dr Harald Hasselmann, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment. "Together with our other products, we will be able to offer nuclear medicine practices and clinics in Germany a fully comprehensive product portfolio for the production of Ga-68 PSMA, once approval has been attained."

"We are pleased to have entered this commercial distribution agreement with Eckert & Ziegler so that, subject to German regulatory approval, we will together be able to deliver a commercial product to German patients living with prostate cancer as efficiently as possible. Partnering with such a capable and patient-centric leader in nuclear medicine uniquely aligns with Telix's mission of helping patients with cancer live longer, better quality lives", explained Telix Chief Executive Officer Dr Christian Behrenbruch.

Illuccix^(R) is offered as a so-called kit preparation for the diagnosis of prostate cancer. For this purpose, Illuccix^(R) enables PSMA-11 to be labelled with the radionuclide Ga-68 directly before injection by medical personnel. After preparing the radiopharmaceutical and injecting it into the patient, tumours that show the so-called prostate-specific membrane antigen can be localised by PET.^[1],[2]